Exit 156 Capital

Exit 156 Capital is a growth equity firm that makes non-controlling investments in small and middle-market companies with proven business models and management teams ready to grow. Founded by entrepreneurs and operators, the firm concentrates on healthcare, agriculture and technology businesses across the United States. It has deployed more than $120 million across more than 12 partnerships, drawing on over 20 years of operating experience and on the founders' record of scaling organisations from $50 million to $7 billion and building companies beyond $120 million in revenue.

Investment activity runs through Fund I, whose portfolio spans sepsis detection, digital therapeutics, urgent-care technology, healthcare staffing, sustainable food technology and body sculpting. The stated approach is hands-on but non-controlling: the firm engages directly with management teams while leaving operational control with founders. Decisions are made within a flat organisational structure designed to move quickly, and the team's own history of building and scaling businesses underpins the diligence applied to each opportunity.

The firm is United States-focused. One structural feature of Fund I sets it apart from comparable vehicles: 5 per cent of investment returns are designated for the College of Saint Benedict and Saint John's University, embedding a charitable commitment in the fund's economics.